Amit Garg1, Vassiliki Papagermanos2, Margaretta Midura2, Andrew Strunk2, Jonathan Merson3. 1. Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York. Electronic address: amgarg@northwell.edu. 2. Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York. 3. Department of Psychiatry, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Abstract
BACKGROUND: Patients with hidradenitis suppurativa (HS) experience chronic pain and have significant physical, emotional, and psychological disease impact. These patients may be at risk for substance abuse. OBJECTIVE: To evaluate substance use disorder (SUD) among patients with HS in the United States. METHODS: This cross-sectional analysis of adult HS patients (n = 32,625) identified using electronic health records data was pulled from a population-based sample of >50 million patients. RESULTS: The prevalence of SUD among patients with HS was 4.0% (1315/32,625) compared to 2.0% (195,260/9,581,640) for patients without HS (P < .001). The most common forms of substance misuse among HS patients were alcohol (630/1315, 47.9% of SUD cases), followed by opioids (430/1315, 32.7% of SUD cases) and cannabis (430/1315, 29.7% of SUD cases). Patients with HS had 1.50 (95% confidence interval 1.42-1.59) times the adjusted odds of SUD compared to patients without HS. Patients with HS had significantly greater odds of SUD across demographic subgroups. The association between HS and SUD was generally stronger for patients 45 to 64 years of age, nonwhites, privately insured, and those without depressive or anxiety disorder. LIMITATIONS: SUD may not be accurately diagnosed. CONCLUSION: Patients with HS have higher odds of SUD and may benefit from periodic screening for substance abuse.
BACKGROUND:Patients with hidradenitis suppurativa (HS) experience chronic pain and have significant physical, emotional, and psychological disease impact. These patients may be at risk for substance abuse. OBJECTIVE: To evaluate substance use disorder (SUD) among patients with HS in the United States. METHODS: This cross-sectional analysis of adult HS patients (n = 32,625) identified using electronic health records data was pulled from a population-based sample of >50 million patients. RESULTS: The prevalence of SUD among patients with HS was 4.0% (1315/32,625) compared to 2.0% (195,260/9,581,640) for patients without HS (P < .001). The most common forms of substance misuse among HS patients were alcohol (630/1315, 47.9% of SUD cases), followed by opioids (430/1315, 32.7% of SUD cases) and cannabis (430/1315, 29.7% of SUD cases). Patients with HS had 1.50 (95% confidence interval 1.42-1.59) times the adjusted odds of SUD compared to patients without HS. Patients with HS had significantly greater odds of SUD across demographic subgroups. The association between HS and SUD was generally stronger for patients 45 to 64 years of age, nonwhites, privately insured, and those without depressive or anxiety disorder. LIMITATIONS: SUD may not be accurately diagnosed. CONCLUSION:Patients with HS have higher odds of SUD and may benefit from periodic screening for substance abuse.
Authors: Erin K Collier; Ram K Parvataneni; Michelle A Lowes; Haley B Naik; Martin Okun; Vivian Y Shi; Jennifer L Hsiao Journal: Am J Obstet Gynecol Date: 2020-09-24 Impact factor: 8.661
Authors: Ali Alikhan; Christopher Sayed; Afsaneh Alavi; Raed Alhusayen; Alain Brassard; Craig Burkhart; Karen Crowell; Daniel B Eisen; Alice B Gottlieb; Iltefat Hamzavi; Paul G Hazen; Tara Jaleel; Alexa B Kimball; Joslyn Kirby; Michelle A Lowes; Robert Micheletti; Angela Miller; Haley B Naik; Dennis Orgill; Yves Poulin Journal: J Am Acad Dermatol Date: 2019-03-11 Impact factor: 15.487
Authors: Rune Kjærsgaard Andersen; Isabella Charlotte Loft; Kristoffer Burgdorf; Christian Erikstrup; Ole B Pedersen; Gregor B E Jemec Journal: Acta Derm Venereol Date: 2021-01-20 Impact factor: 3.875
Authors: Chidubem A V Okeke; Jonathan P Williams; Callyn U Iwuala; Pearl K Igwe; Raveena Khanna; Jessica D Perry; Ginette A Okoye; Angel S Byrd Journal: Front Immunol Date: 2022-03-29 Impact factor: 7.561